Biopharmaceuticals for prevention of COVID-19:A scoping review  

作　　者：Afsaneh Farjami Soheila Montazersaheb Saiedeh Razi Soofiyani Parvin Akbarzadehlaleh Sara Salatin 

机构地区：[1]Food and Drug Safety Research Center,Tabriz University of Medical Science,Tabriz,Iran [2]Pharmaceutical Analysis Research Center,Tabriz University of Medical Science,Tabriz,Iran [3]Molecular Medicine Research Center,Tabriz University of Medical Science,Tabriz,Iran [4]Department of Molecular Medicine,Faculty of Advanced Medical Sciences,Tabriz University of Medical Sciences,Tabriz,Iran [5]Clinical Research Development Unit Sina Educational,Research and Treatment Center,Tabriz University of Medical Sciences,Tabriz,Iran [6]Department of Pharmaceutical Biotechnology,Faculty of Pharmacy,Tabriz University of Medical Science,Tabriz,Iran [7]Neurosciences Research Center(NSRC),Tabriz University of Medical Sciences,Tabriz,Iran

出　　处：《Asian Pacific Journal of Tropical Medicine》2022年第6期245-265,共21页亚太热带医药杂志（英文版）

基　　金：financial support from the Food and Drug Safety Research Center at Tabriz University of Medical Sciences(Grant No.66317).

摘　　要：The COVID-19 epidemic caused by SARS-CoV-2 virus has turned into a worldwide pandemic.Therefore,health officials all around the world have strived for developing efficient preventive and treatment methods to deal with this global crisis.Amongst them,monoclonal antibodies,anti-TNFs,and convalescent plasma appear to be effective against this disease.In addition,clinical trials are currently being conducted for viral targeting vaccines.This review summarizes major advances using biopharmaceuticals in the treatment and prevention strategies against COVID-19 that have occurred in the global medicinal system from its introduction until March 2022.

关 键 词：COVID-19 SARS-CoV-2 BIOPHARMACEUTICALS Monoclonal antibodies Anti-TNFs Convalescent plasma VACCINE 

分 类 号：R978.7[医药卫生—药品]